Resumen:
Patients with advanced cancer often continue to choose aggressive interventions and/or treatments up until
the final stages of life. This clinical approach may compromise the preservation of a patient¿s quality of life,
and secondarily, contributes to higher healthcare costs. Therefore, the ethics of enrolling terminal cancer
patients in clinical trials which are testing new, aggressive chemotherapy agents requires careful
discussion between the Oncology and the Palliative Care team. We present the case of a patient with
stomach cancer admitted to a clinical trial at a very advanced stage of her disease. A number of clinical
and ethical difficulties encountered by the PC team are discussed as well as possible solutions